Researchers at GSK’s global research and development centers will gain access to Aureus’ Knowledge databases including AurSCOPE GPCR, Ion Channel, hERG, and ADME/Drug-Drug Interactions.
In addition, GSK has licensed the recently released AurSCOPE Kinase product making it the first customer of this knowledge base which is of major importance for oncology and other diseases.
"AurSCOPE knowledge databases are comprised of detailed quantitative biological and chemical data," said Dr. Andre Michel, CEO of Aureus Pharma.
"With its unrivalled level of quality, Aureus Pharma’s knowledge driven discovery platform provides drug discovery teams with comprehensive information to accelerate both the drug discovery and development process."
"We are pleased that GSK has selected Aureus Pharma as their global solution provider of integrated knowledge databases."
The addition of a pharmaceutical R&D world leader, such as GSK, to Aureus’ growing list of customers is further confirmation that AurSCOPE is becoming accepted as the knowledge base of choice for pharmaceutical and biotechnology organizations.